Article
Oncology
Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu
Summary: This study aimed to evaluate the safety, dose-limiting toxicity, maximum tolerated dose, and preliminary effect of nanoparticle albumin-bound paclitaxel in combination with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. The results showed that this treatment regimen was effective and well-tolerated for patients with locally advanced esophageal squamous cell carcinoma.
Article
Oncology
Jung Hyun Jo, Dawoon E. Jung, Hee Seung Lee, Soo Been Park, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Sangsook Cho, Si Young Song
Summary: This phase I/II study evaluated the safety and efficacy of a new HDAC inhibitor called ivaltinostat in combination with gemcitabine and erlotinib for advanced PDAC. The study found that this combination therapy showed potential as a treatment option for PDAC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Medicine, Research & Experimental
He Huang, Cai-Ping Nie, Xiu-Feng Liu, Bin Song, Jian-Hui Yue, Jing-Xiao Xu, Jia He, Kui Li, Yan-Ling Feng, Ting Wan, Min Zheng, Yan-Na Zhang, Wei-Jun Ye, Jun-Dong Li, Yan-Fang Li, Jun-Yun Li, Xin-Ping Cao, Zhi-Min Liu, Xiao-Shi Zhang, Qing Liu, Xi Zhang, Ji-Hong Liu, Jiang Li
Summary: This study explored the safety and feasibility of infusion of autogenous tumor-infiltrating lymphocytes (TILs) following concurrent chemoradiotherapy (CCRT) in patients with locally advanced cervical cancer (CC). The results showed that TIL-based adoptive cell therapy (ACT) may be a potentially effective adjuvant treatment for locally advanced CC patients.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Carlos Contreras-Romero, Eloy-Andres Perez-Yepez, Antonio Daniel Martinez-Gutierrez, Alma Campos-Parra, Alejandro Zentella-Dehesa, Nadia Jacobo-Herrera, Cesar Lopez-Camarillo, Guillermo Corredor-Alonso, Jaime Martinez-Coronel, Mauricio Rodriguez-Dorantes, David Cantu de Leon, Carlos Perez-Plasencia
Summary: Cervical cancer remains one of the leading causes of mortality in women despite efforts in screening and early detection. This study identified specific gene methylation patterns associated with treatment response and prognosis, suggesting their potential as molecular markers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Otorhinolaryngology
Mei-Kim Ang, Jose Enrique Montoya, Ekkasit Tharavichitkul, Cindy Lim, Terence Tan, Lan Ying Wang, Joseph Wee, Yoke-Lim Soong, Kam-Weng Fong, Quan Sing Ng, Daniel Shao-Weng Tan, Chee-Keong Toh, Eng-Huat Tan, Wan-Teck Lim
Summary: In this study, the combination of nimotuzumab with cisplatin and radiotherapy was found to be safe and effective in treating locally advanced head and neck squamous cell carcinoma, with high response rates observed in patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Review
Oncology
Warren Bacorro, Kathleen Baldivia, Kelvin Ken Yu, Jocelyn Mariano, Gil Gonzalez, Teresa Sy Ortin
Summary: This study synthesized evidence on treatment outcomes with radiotherapy (RT) with or without chemotherapy (ChT) in locally advanced cervical cancer (LACC) patients who are intolerant to cisplatin. The results showed that the complete response rate and survival rate in these patients were comparable to those without contraindications to cisplatin. Chemoradiation therapy (CRT) had a better survival rate than RT alone, and nodal boost (NB) improved survival rate compared to no NB. Carboplatin CRT had lower survival rate but better ChT compliance compared to other interventions. ChT compliance was better in renal failure patients than elderly cohorts. RT compliance was lower with CRT than RT alone, and higher with NB than no NB. Meta-regression analysis indicated that ChT and NB were significant positive factors for survival, and NB was associated with better RT compliance.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Wencheng Zhang, Cihui Yan, Tian Zhang, Xi Chen, Jie Dong, Jingjing Zhao, Dong Han, Jun Wang, Gang Zhao, Fuliang Cao, Dejun Zhou, Hongjing Jiang, Peng Tang, Lujun Zhao, Zhiyong Yuan, Quanren Wang, Ping Wang, Qingsong Pang
Summary: Combining concurrent chemoradiotherapy with the anti-PD-1 antibody camrelizumab as first-line treatment for locally advanced esophageal squamous cell carcinoma is safe and feasible, showing promising antitumour efficacy and manageable adverse effects. Biomarkers such as tumor PD-L1 expression and specific immune cells in peripheral blood were associated with overall survival, indicating the potential of this treatment strategy for further study.
Review
Immunology
Mengjie Jiang, Yujie Hu, Gang Lin, Chao Chen, Huafeng Li
Summary: This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, outlines the clinical trials that merit attention, and discusses unresolved issues and future research directions in this field. The findings suggest that radio-immunotherapy combination may improve treatment outcomes, highlighting the importance of patient selection and the need for further research to optimize treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Lei Zhang, Jun Ma, Di Zhou, Junjun Zhou, Bin Hu, Xiumei Ma, Jianming Tang, Yongrui Bai, Haiyan Chen, Ying Jing
Summary: Radiotherapy is the primary method for treating locally advanced CSCC. However, a significant number of patients do not respond well to this treatment. A study using single-nucleus RNA-seq reveals that the expression of a neural-like progenitor program is significantly increased in tumor cells after radiotherapy, especially in nonresponding patients. Further analysis confirms the association of this program with poor prognosis in CSCC patients, and in vitro experiments demonstrate that downregulation of a key gene from this program is associated with decreased cell growth and increased radiation sensitivity. Immunohistochemical staining validates the role of key genes from the immunomodulatory program as regulators of radiosensitivity. These findings suggest that the expression of NRP in CSCC can predict the efficacy of radiotherapy.
Article
Oncology
Seung Yeun Chung, Kyoung-Jin Kim, Jinsil Seong
Summary: This study investigated biomarkers for predicting treatment outcomes in patients with locally advanced HCC who received liver-directed combined radiotherapy (LDCRT). The study identified baseline sPD-L1, sPD-L1 fold change, and cfDNA fold-change values as potential biomarkers for predicting post-treatment progression in HCC patients. These biomarkers, along with clinical factors, may be useful for developing a biomarker-driven treatment paradigm for locally advanced HCC.
Article
Oncology
Jidong Zhao, Ming He, Jie Li, Dan Li, Yang Zhao, Xinhui Li, Xiangmei Zhang, Xin Chen, Yunjiang Liu, Liyan Zhao
Summary: In this study, apatinib combined with neoadjuvant chemotherapy showed significantly increased objective response rate in patients with locally advanced esophageal squamous cell carcinoma. The addition of apatinib also led to higher pathological complete response rate compared to chemotherapy alone. Both groups had similar incidences of toxic effects and surgical outcomes, suggesting the potential benefit of anti-angiogenesis therapy in esophageal cancer.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2022)
Article
Multidisciplinary Sciences
Yue Zhang, Shasha Fan, Minjie Shan, Wen Zou, Yeqian Feng, Tao Hou, Xianling Liu, Jingjing Wang
Summary: This study evaluated the efficacy and safety of cisplatin and nedaplatin in three-week doublet agent concurrent chemoradiotherapy (CCRT) for patients with locally advanced cervical cancer (LACC). Clinical outcomes were analyzed, and propensity score matching analysis was used to compare the two groups. The study found that doublet agent CCRT is feasible, safe, and shows high efficacy in LACC patients. Cisplatin has a trend of better prognosis, suggesting it may be preferred over nedaplatin.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Noriyuki Okonogi, Kazutoshi Murata, Shigeru Yamada, Yuji Habu, Makoto Hori, Tomoya Kurokawa, Yosuke Inaba, Tadami Fujiwara, Yasuhisa Fujii, Michiko Hanawa, Yohei Kawasaki, Yoko Hattori, Kazuko Suzuki, Kyoko Tsuyuki, Masaru Wakatsuki, Masashi Koto, Sumitaka Hasegawa, Hitoshi Ishikawa, Hideki Hanaoka, Makio Shozu, Hiroshi Tsuji, Hirokazu Usui
Summary: We conducted a phase Ib study to evaluate the safety of combining carbon-ion RT (CIRT) with durvalumab in patients with locally advanced cervical cancer. Three patients were enrolled and completed the treatment without interruption. One patient developed hypothyroidism, but recovered after treatment. No other serious adverse events (SAEs) were observed. All three patients achieved complete responses within the CIRT region. Further research is needed due to the small sample size of this study.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jing Hu, Zhe Chen, Jiaming Lv, Zhen Zheng, Yanping Bei, Xue Chen, Lu Zheng, Wenjie Song, Yunbao Xu
Summary: The combination of nimotuzumab with chemoradiotherapy is safe and effective in treating locally advanced cervical esophageal squamous cell carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Masahiko Okamoto, Shintaro Shiba, Daijiro Kobayashi, Yuhei Miyasaka, Shohei Okazaki, Kei Shibuya, Tatsuya Ohno
Summary: This study evaluated the clinical impact of carbon-ion radiotherapy (CIRT) with concurrent chemotherapy for locally advanced unresectable pancreatic cancer (URPC). The results showed that CIRT has survival benefits for URPC even in the multiagent chemotherapy era.
Article
Oncology
Leonard M. da Silva, Emilio M. Pereira, Paulo G. O. Salles, Ran Godrich, Rodrigo Ceballos, Jeremy D. Kunz, Adam Casson, Julian Viret, Sarat Chandarlapaty, Carlos Gil Ferreira, Bruno Ferrari, Brandon Rothrock, Patricia Raciti, Victor Reuter, Belma Dogdas, George DeMuth, Jillian Sue, Christopher Kanan, Leo Grady, Thomas J. Fuchs, Jorge S. Reis-Filho
Summary: AI-based system Paige Prostate shows high sensitivity and NPV in the diagnosis of prostate cancer, leading to potential improvement in patient care. It can accurately classify histopathology slides into benign or suspicious categories, reducing diagnostic time and improving efficiency.
JOURNAL OF PATHOLOGY
(2021)
Review
Endocrinology & Metabolism
Elisa B. Lamback, Sergio Altino de Almeida, Ricardo Terra, Carlos Gil Ferreira, Vera Luiza Capelozzi, Rui Haddad, Monica R. Gadelha
Summary: Cyclic Cushing's syndrome caused by thymic carcinoid is a rare disorder, which may require aggressive treatment due to the aggressive nature of this type of tumor.
ARCHIVES OF ENDOCRINOLOGY METABOLISM
(2021)
Article
Multidisciplinary Sciences
Gabriella Campos-do-Carmo, Aretha Brito Nobre, Tullia Cuzzi, Giuseppe Argenziano, Carlos Gil Ferreira, Luiz Claudio Santos Thuler
Summary: Clinical and dermoscopic parameters have been identified to aid in the diagnosis of small size melanoma, including criteria such as streaks and structureless areas. These factors can be particularly useful for diagnosing this subset of challenging small melanomas.
Article
Oncology
Rodrigo Otavio Araujo, Fernando Meton Vieira, Ana Paula Victorino, Claudia Torres, Ivanir Martins, Simone Guaraldi, Marcus Valadao, Eduardo Linhares, Carlos Gil Ferreira, Luiz Claudio Thuler
Summary: This study aimed to compare the impact of two different neoadjuvant chemoradiotherapy (neoCRT) regimens on the quality of life (QOL) in patients with locally advanced rectal cancer. The results showed that the QOL was equivalent between the two treatment groups after neoCRT, with the exception of better micturition problems, gastrointestinal problems, defecation problems, and sexual satisfaction in the capecitabine group. Overall, the QOL improved after neoCRT but decreased following rectal resection, returning to basal levels at late evaluation. Fecal incontinence was high after sphincter preservation.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Health Care Sciences & Services
Marina Kelner, Bruna Carvalho da Silva, Tatiane Montella, Pedro Nazareth Aguiar, Gilberto Lopes, Carlos G. Ferreira, Pedro De Marchi
Summary: This study compares the cost of treating advanced lung cancer in Brazil with the reimbursement provided by the Brazilian public healthcare system. It finds that the cost of the best treatment available is significantly higher than the amount reimbursed by the system.
VALUE IN HEALTH REGIONAL ISSUES
(2023)
Article
Oncology
Lilian Faroni, Carlos Gil Ferreira, Fabio Moraes, Clarissa Baldotto, Mauro Zukin, Veronica Aran, Luiz Henrique Araujo
Summary: The study examined the real-world outcomes of using SBRT for lung lesions in a Brazilian institution. The results showed that SBRT was effective in achieving high local control rates and had acceptable toxicity for treating malignant lung lesions in Latin America.
JCO GLOBAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares
Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.
Article
Health Care Sciences & Services
Flavia Amaral Duarte, Pedro Nazareth Aguiar Junior, Rodrigo Dienstmann, Carlos Gil Ferreira
Summary: Precision medicine provides personalized interventions based on patients' or tumors' characteristics, but it faces challenges in becoming a global reality, with the main issue being inequities in access to genomic testing. Disparities exist between regions and populations, and socioeconomic factors play a significant role in this inequality.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2023)
Article
Oncology
Carlos Gil Ferreira, Marcia Datz Abadi, Paula de Mendonca Batista, Fernando Brandao Serra, Rodrigo Buzzatti Peixoto, Lucas Miyake Okumura, Erica Regina Cerqueira
Summary: This study focused on describing the journey and survival rates of patients with advanced NSCLC treated in the Brazilian private health care system. It found that the majority of patients were between 60 and 69 years old, with a higher proportion of men, and most were diagnosed with stage IV NSCLC. Chemotherapy was the most common treatment regimen, with median overall survival of 11.5 months and 6 months for stage II and IV NSCLC, respectively.
JCO GLOBAL ONCOLOGY
(2021)
Article
Oncology
Aline B. Lara Gongora, Gustavo Werutsky, Denis L. Jardim, Angelica Nogueira-Rodrigues, Carlos H. Barrios, Clarissa Mathias, Fernando Maluf, Rachel Riechelmann, Mauricio Fraga, Henry Gomes, William N. William, Camilla A. F. Yamada, Gilberto de Castro Jr, Daniela D. Rosa, Andreia C. de Melo, Raul Sala, Eva Bustamante, Denisse Bretel, Oscar Arrieta, Andres F. Cardona, Diogo A. Bastos
Summary: This study investigated the impact of COVID-19 on oncology clinical trials in Latin America, revealing that most research centers suspended accruals for some studies, largely due to sponsors' decisions. Clinical trials' routine was affected by factors such as medical visits cancelation, reduction of patients' attendance, reduction of other specialties' availability, and alterations on follow-up processes.
JCO GLOBAL ONCOLOGY
(2021)
Article
Oncology
Gustavo Werutsky, Carlos H. Barrios, Andres F. Cardona, Andre Albergaria, Alfonso Valencia, Carlos G. Ferreira, Christian Rolfo, Evandro de Azambuja, Gabriel A. Rabinovich, Georgina Sposetti, Oscar Arrieta, Rodrigo Dienstmann, Taiane F. Rebelatto, Valeria Denninghoff, Veronica Aran, Eduardo Cazap
Summary: The challenges in health systems in Latin America and the Caribbean, including accessibility, inequity, segmentation, and poverty, are similar across the region. The adoption of digital health tools holds promise for more precise interventions and improved health outcomes, but it is still at an early stage.
Article
Medicine, General & Internal
Veronica Aran, Mariano Zalis, Tatiane Montella, Carlos Augusto Moreira de Sousa, Bruno L. Ferrari, Carlos Gil Ferreira
Summary: This study investigated the incidence of KRAS mutations and concomitant mutations in advanced non-small cell lung adenocarcinoma patients. Results showed a higher prevalence of male patients, with 20.86% of samples having mutant KRAS and 33.3% of mutant KRAS samples showing other simultaneous mutations. Further research is needed to explore the significance of these genomic alterations in patient prognosis and treatment response.
MEDICINA-LITHUANIA
(2021)
Article
Medicine, General & Internal
Thales Pardini Fagundes, Ronniel Morais Albuquerque, Diego Lopes Paim Miranda, Luciana Castro Garcia Landeiro, Gabriel Souza Fontes Ayres, Caenna Correa E. Correia, Angelica Nogueira-Rodrigues
Summary: This article provides recommendations for cancer screening in the face of the possibility of new waves of COVID-19, including breast cancer, cervical cancer, colorectal cancer, and prostate cancer screening. It suggests maintaining routine screening in high-risk patients, but considering longer screening intervals in average-risk individuals.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
(2021)
Meeting Abstract
Oncology
L. Faroni, A. Rosa, V. Aran, C. Gil Ferreira
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Bruno L. Ferrari, Carlos Gil Ferreira, Marcia Menezes, Pedro De Marchi, Jorge Canedo, Andreia Cristina de Melo, Alexandre A. Jacome, Tomas Reinert, Rafael Duarte Paes, Barbara Sodre, Carlos H. Barrios, Rodrigo Dienstmann
Summary: The study on COVID-19 patients with cancer in Brazil revealed that age, smoking history, and disease severity are significant determinants of mortality, affecting outcomes similar to the general population.
JCO GLOBAL ONCOLOGY
(2021)